SUBSCRIBE
SUBSCRIBE
News   Drug Development

Genentech, Inc. (JOBS), Biogen Idec, Inc. (Massachusetts)'s Rituxan Meets Goal in Late Stage Leukemia Trial

October 7, 2008 | 
1 min read
SOUTH SAN FRANCISCO, Calif. -Genentech Inc. and Biogen Idec Inc. said Tuesday their cancer drug Rituxan slowed the progress of chronic lymphocytic leukemia in a late stage clinical trial, meeting its primary goal.
Clinical research Phase 3
MORE ON THIS TOPIC
Target concept vector illustration. Business goal, marketing strategy, digital aim, bullseye accuracy, cyber challenge, innovation target, focus objective, dart board, internet market.
Phase 3
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
August 13, 2026
 · 
3 min read
 · 
Gabrielle Masson
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
Words IPO (Initial public offering) with the trading data on the background.
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 12, 2026
 · 
1 min read
 · 
Gabrielle Masson